PMID- 8043944
OWN - NLM
STAT- MEDLINE
DCOM- 19940830
LR  - 20181113
IS  - 1170-229X (Print)
IS  - 1170-229X (Linking)
VI  - 4
IP  - 5
DP  - 1994 May
TI  - Pimobendan. A review of its pharmacology and therapeutic potential in congestive 
      heart failure.
PG  - 417-41
AB  - Pimobendan is a novel cardiotonic vasodilator (inodilator) which derives its 
      inotropic activity from a combination of phosphodiesterase III inhibition and 
      sensitisation of myocardial contractile proteins to calcium. The acute 
      haemodynamic benefits of pimobendan (2.5 to 10mg orally; 5 to 10mg intravenously) 
      seen in patients maintained on conventional diuretic, digitalis and vasodilator 
      therapy for chronic heart failure (increases in cardiac output and stroke volume, 
      and reductions in left ventricular preload and afterload) persisted on short term 
      (1 month) therapy, and showed only limited evidence of attenuation on longer term 
      (6 months) oral therapy with pimobendan 2.5 or 5mg twice daily. Adjunctive 
      therapy with pimobendan 1.25 to 5mg twice daily for periods of 3 to 6 months 
      improved exercise tolerance on symptom-limited exercise testing, New York Heart 
      Association (NYHA) functional class, and quality of life, and additionally 
      reduced the need for hospitalisation in patients with moderate to severe chronic 
      heart failure. Pimobendan appears to be well tolerated at therapeutic doses (1.25 
      to 5mg twice daily) in patients with chronic heart failure, and preliminary 
      indications suggest that it is largely devoid of the proarrhythmic effects of 
      classical phosphodiesterase III inhibitors. Although information regarding the 
      long term effects of pimobendan on mortality is currently lacking, the drug 
      nevertheless shows potential benefit as an adjunctive therapy in patients with 
      chronic heart failure.
FAU - Fitton, A
AU  - Fitton A
AD  - Adis International Limited, Auckland, New Zealand.
FAU - Brogden, R N
AU  - Brogden RN
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs Aging
JT  - Drugs & aging
JID - 9102074
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Phosphodiesterase Inhibitors)
RN  - 0 (Pyridazines)
RN  - 34AP3BBP9T (pimobendan)
RN  - 77469-70-6 (UD CG 212 Cl)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Cardiotonic Agents/pharmacokinetics/*pharmacology/therapeutic use
MH  - Clinical Trials as Topic
MH  - Drug Interactions
MH  - Electrophysiology
MH  - Heart Failure/*drug therapy
MH  - Hemodynamics/drug effects
MH  - Humans
MH  - Intestinal Absorption
MH  - Liver/metabolism
MH  - Myocardium/metabolism
MH  - Phosphodiesterase Inhibitors/pharmacokinetics/*pharmacology/therapeutic use
MH  - Pyridazines/metabolism/pharmacokinetics/*pharmacology/therapeutic use
RF  - 133
EDAT- 1994/05/01 00:00
MHDA- 1994/05/01 00:01
CRDT- 1994/05/01 00:00
PHST- 1994/05/01 00:00 [pubmed]
PHST- 1994/05/01 00:01 [medline]
PHST- 1994/05/01 00:00 [entrez]
AID - 10.2165/00002512-199404050-00007 [doi]
PST - ppublish
SO  - Drugs Aging. 1994 May;4(5):417-41. doi: 10.2165/00002512-199404050-00007.